Job title: Senior Director, US Medical Affairs
Smitha Sivaraman, PhD is an experienced, versatile medical affairs leader with over 22 years of experience in Oncology within industry and academia. Smitha leads the US medical affairs strategy and execution for the launch of Incyte’s FGFR inhibitor Pemigatinib in CCA and pipeline activities within the FGFR program at Incyte. She has contributed to multiple launches for Ruxolitinib (Jakafi) in myelofibrosis, polycythemia vera and steroid refractory acute GVHD in different capacities at Incyte. She has diversified experience within medical affairs leading MSL teams, medical affairs training and conducting Phase IV studies and real world outcome approaches. Smitha enjoys fostering talent, mentoring and creating solution oriented outcomes.